Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorUniversity of Southern California

About this trial

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.

Eligibility criteria

Qualifiers

All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer

Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and/or immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura [ITP], etc.) are involved

Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], Crohn's disease) and not taking any immunosuppressive medications

Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project

Disqualifiers

Unable to give informed consent to specimen collection

Known human immunodeficiency virus (HIV) positive status

Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers

Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Laboratory Biomarker Analysis
  • Questionnaire Administration

Treatment groups

625 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Southern California

Lead sponsor

National Cancer Institute (NCI)

Collaborator